Skip to content

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04827537
Enrollment
200
Registered
2021-04-01
Start date
2021-01-01
Completion date
2027-12-31
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giardia Lamblia Infection

Brief summary

20-hydroxyecdysone is an ecdysteroid hormone found in invertebrates and plants. 20-hydroxyecdysone exhibits a broad range of biological properties in various in vitro and in vivo models, including anabolic, antioxidant, anti-inflammatory, immunomodulatory, anti-obesity and antidiabetic activities, in addition to acting as neuroprotective and hepatoprotective agent. Ecdysteroids are widely used by athletes as dietary supplements to increase strength and muscle mass during resistance training, to reduce fatigue and to ease recovery. Mhashilkar AS et al. (2016) were revealed anti-parasitic activity of 20-hydroxyecdysone against the human filarial parasites. According to recent searches in academic databases and medical search engines (Google, www.google.com; PubMed, www.ncbi.nlm.nih.gov/pubmed; and Medline, www.medline.com), no studies have been conducted to assess the anti-protozoal activity of 20-hydroxyecdysone. The aim of the study is to assess anti-protozoal activity of 20-hydroxyecdysone in water sports athletes with giardiasis.

Detailed description

The randomized, double-blinded, placebo-controlled clinical study will be conducted by the Uzbek State University of Physical Education and Sport, Institute of the Chemistry of Plant Substances named acad. S. Yu. Yunusov and Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan Both informed and written consents will be obtained from the participants. Study participants will be included about 200 athletes aged 18 to 27 years with giardiasis. All the participants will be residents of Uzbekistan. Diagnosis of giardiasis will be based on the results of parasitological examination. Inclusion criteria:presence of giardia intestinalis in the stool samples of participant. The exclusion criteria: chronic and acute infectious diseases, endocrine diseases, congenital diseases, allergic dermatitis, bronchial asthma, allergic rhinitis and/or conjunctivitis, other skin disorders, history of using vitamin D supplements within three months ago, or use of any medication influencing endocrine parameters. Measurement of anthropometric indices Demographic data will be obtained in the survey included age, gender, and body mass index (BMI) calculated as weight (kg)/height2 (m2). Blood Sample Collection and Storage Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. All blood samples will be collected before and after therapy. 200 water sports athletes with Giardia infection will be randomized from 1 to 3 groups to receive 20-hydroxyecdysone, metronidazole and placebo preparations, respectively

Interventions

DRUG20-hydroxyecdysone Oral

100 mg (one pill) x two times a day orally, 10 consecutive days

500 mg (one pill) x two times a day orally, 10 consecutive days

100 mg (one pill) x two times a day orally, 10 consecutive days

Sponsors

Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 27 Years
Healthy volunteers
No

Inclusion criteria

\- a presence of giardia lamblia in stool samples of partisipants

Exclusion criteria

* chronic and acute infectious diseases, * endocrine diseases, congenital diseases, * allergic dermatitis, * bronchial asthma, * allergic rhinitis and/or conjunctivitis, * other skin disorders, * history of using vitamin D supplements within three months ago, or use of any medication influencing endocrine parameters.

Design outcomes

Primary

MeasureTime frameDescription
Anti-protozoal effect of steroid hormone 20-hydroxyecdysoneup to 24 monthsDetection of Anti-protozoal effect of steroid hormone 20-hydroxyecdysone

Countries

Uzbekistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026